Zacks: Brokerages Expect Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Will Post Earnings of -$0.68 Per Share
Analysts predict that Aldeyra Therapeutics, Inc (NASDAQ:ALDX) will post ($0.68) earnings per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Aldeyra Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.73) and the highest estimate coming in at ($0.62). Aldeyra Therapeutics posted earnings per share of ($0.39) during the same quarter last year, which indicates a negative year-over-year growth rate of 74.4%. The firm is expected to announce its next earnings results on Friday, March 13th.
According to Zacks, analysts expect that Aldeyra Therapeutics will report full year earnings of ($2.44) per share for the current financial year, with EPS estimates ranging from ($2.49) to ($2.39). For the next fiscal year, analysts expect that the firm will report earnings of ($2.37) per share, with EPS estimates ranging from ($2.70) to ($1.91). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Aldeyra Therapeutics.
Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.14).
In other news, CEO Todd C. Brady purchased 20,000 shares of the stock in a transaction on Monday, December 16th. The shares were acquired at an average price of $5.83 per share, for a total transaction of $116,600.00. Following the completion of the transaction, the chief executive officer now directly owns 652,216 shares of the company’s stock, valued at approximately $3,802,419.28. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 13.50% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALDX. Point72 Asset Management L.P. purchased a new stake in Aldeyra Therapeutics during the second quarter valued at about $1,950,000. Millennium Management LLC raised its position in Aldeyra Therapeutics by 122.0% during the third quarter. Millennium Management LLC now owns 533,632 shares of the biotechnology company’s stock valued at $2,812,000 after purchasing an additional 293,278 shares in the last quarter. BlackRock Inc. raised its position in Aldeyra Therapeutics by 14.6% during the second quarter. BlackRock Inc. now owns 1,538,466 shares of the biotechnology company’s stock valued at $9,231,000 after purchasing an additional 196,463 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Aldeyra Therapeutics during the second quarter valued at about $541,000. Finally, Vanguard Group Inc. raised its position in Aldeyra Therapeutics by 4.0% during the second quarter. Vanguard Group Inc. now owns 1,111,944 shares of the biotechnology company’s stock valued at $6,671,000 after purchasing an additional 42,869 shares in the last quarter. Institutional investors and hedge funds own 60.34% of the company’s stock.
Shares of ALDX stock traded up $0.06 on Wednesday, reaching $6.25. The company’s stock had a trading volume of 177,600 shares, compared to its average volume of 185,520. The company has a quick ratio of 6.36, a current ratio of 6.36 and a debt-to-equity ratio of 0.28. Aldeyra Therapeutics has a 12-month low of $4.31 and a 12-month high of $12.79. The company has a market capitalization of $172.47 million, a P/E ratio of -3.49 and a beta of 0.89. The stock’s 50 day simple moving average is $5.92 and its 200-day simple moving average is $5.63.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
Further Reading: What is a dividend reinvestment plan?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.